831P Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp

Koch, Elizabeth; Arteaga, Diana P.; Vilbert, Maysa; Lajkosz, K.; Muniz, Thiago Pimentel; Hirsch, Ian; Ribeiro, M.F. Silva Almeida; Mantle, L.; Anczurowski, Mark; Hogg, David; Saibil, S.; Spreafico, Anna; Krema, Hatem; Marcus, Butler

doi:10.1016/j.annonc.2022.07.957

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are high expectations regarding the new treatment option for advanced HLA-A*02:01 UM with tebentafusp. Nevertheless, the optimal sequence of tebentafusp and combined ICI is unknown ( 17 , 18 ). We have seen an unexpectedly rapid and profound response in our patient to combined ICI after previous tebentafusp therapy and we would like to outline possible reasons that might argue for the use of combined ICI in case of progression to tebentafusp.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report

et al. 2023

View full text Add to dashboard Cite

Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, tebentafusp, has been approved for the treatment of HLA-A*02:01 metastatic or unresectable UM. While the treatment regime is complex with weekly administrations and close monitoring, the response rate is limited. Only a few data exist on combined ICI in UM after previous progression on tebentafusp. In this case report, we present a patient with metastatic UM who first suffered extensive progression under treatment with tebentafusp but in the following had an excellent response to combined ICI. We discuss possible interactions that could explain responsiveness to ICI after pretreatment with tebentafusp in advanced UM.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In a small, single center retrospective cohort study comparing retrospectively 10 patients in each group treated by tebentafusp followed by ICI and vice versa, there was a significant survival benefit for the patients receiving ICI after progressive disease under tebentafusp ( 17 ).…”

Section: Introductionmentioning

confidence: 99%